AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9299652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (400 micrograms, 4 times daily for 3 days)
Number of subjects: 50
Study 9299652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 50
Study 8285776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised racemic adrenaline
Number of subjects: 29
Study 8285776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31819393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory PEP (OPEP) therapy
Number of subjects: 273
Study 31819393 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP therapy
Number of subjects: 273
Study 31819393 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP ± OM therapy
Number of subjects: 273
Study 31819393 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 273
Study 29360492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur (TC)
Number of subjects: 90
Study 29360492 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur (Db)
Number of subjects: 90
Study 29360492 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance PoGo discs (PG)
Number of subjects: 90
Study 29360492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex discs (S)
Number of subjects: 90
Study 29360492 — intervention group
Group type: COMPARATOR
Intervention: Mylar strip (Control)
Number of subjects: 90
Study 26988629 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 24701581 — intervention group
Group type: COMPARATOR
Intervention: 3MS (minimal supervision)
Number of subjects: 351
Study 24701581 — intervention group
Group type: COMPARATOR
Intervention: 3WS (with supervision)
Number of subjects: 351
Study 22878749 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 1000 mg daily
Number of subjects: 27
Study 22878749 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 1000 mg daily plus erlotinib 150 mg
Number of subjects: 27
Study 20972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (group A)
Number of subjects: 132
Study 20972904 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group B)
Number of subjects: 132
Study 17097647 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) alone (100 mg/day from day 3 to day 7; n = 56)
Number of subjects: 63
Study 17097647 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) in combination with pure FSH (75 IU on day 3 and day 8; n = 54)
Number of subjects: 63
Study 17097647 — intervention group
Group type: EXPERIMENTAL
Intervention: No stimulation (n = 35)
Number of subjects: 63
Study 17097647 — intervention group
Group type: COMPARATOR
Intervention: No treatment (parous women, n = 18)
Number of subjects: 63
Study 16275192 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 23
Study 16275192 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine infusion
Number of subjects: 23
Study 16275192 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine bolus
Number of subjects: 23
Study 12688625 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group (educational package and mite allergen-impermeable mattress encasings)
Number of subjects: 696
Study 12688625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 696
Study 9950610 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal grating acuity at age 1 year
Number of subjects: 575
Study 9950610 — intervention group
Group type: COMPARATOR
Intervention: No measurable TAC grating acuity at age 1 year
Number of subjects: 575
Study 9950610 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurable grating acuity <1.6 cyc/deg at age 1 year
Number of subjects: 575
Study 8850659 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 87
Study 8850659 — intervention group
Group type: COMPARATOR
Intervention: PTA and stent placement
Number of subjects: 87
Study 2407957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (75 mg per day)
Number of subjects: 202
Study 2407957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 394752 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 800 microgram daily
Number of subjects: 95
Study 394752 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 400 microgram daily
Number of subjects: 95
Study 394752 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study 394752 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 400 microgram to 800 microgram
Number of subjects: 95
Study 394752 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 95
Study 31500588 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 86
Study 28780504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical rehabilitation (90 min/day, Monday to Friday)
Number of subjects: 308
Study 28780504 — intervention group
Group type: COMPARATOR
Intervention: Standard physical rehabilitation (30 min/day, Monday to Friday)
Number of subjects: 308
Study 26473625 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week)
Number of subjects: 646
Study 26473625 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg every 2 weeks)
Number of subjects: 646
Study 25260444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard inguinal varicocelectomy plus oral L-carnitine therapy (250 mg 3 times a day for 6 months)
Number of subjects: 100
Study 25260444 — intervention group
Group type: COMPARATOR
Intervention: Standard inguinal varicocelectomy
Number of subjects: 100
Study 22552034 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplementation (80 mg daily for 6 weeks)
Number of subjects: 24
Study 22552034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19959293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency, high-intensity transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 200
Study 19959293 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacological treatment (IV opioids)
Number of subjects: 200
Study 18166126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (nonabsorbed antifungal drug)
Number of subjects: 35
Study 18166126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 16325696 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK2 V617F mutation-positive patients
Number of subjects: 806
Study 16325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 806
Study 16325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide therapy
Number of subjects: 806
Study 16325696 — intervention group
Group type: COMPARATOR
Intervention: JAK2 V617F mutation-negative patients
Number of subjects: 806
Study 12045085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular droperidol 2.5 mg
Number of subjects: 40
Study 12045085 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dimenhydrinate 50 mg
Number of subjects: 40
Study 9524997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel (twice daily for 7 days)
Number of subjects: 31
Study 9524997 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (250 mg, three times daily for 7 days)
Number of subjects: 31
Study 9524997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel
Number of subjects: 31
Study 9524997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole and 0.75% metronidazole vaginal gel
Number of subjects: 31
Study 8585295 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate adsorbed vaccine
Number of subjects: 313
Study 8585295 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide adsorbed vaccine
Number of subjects: 313
Study 2533896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg t.d.s.
Number of subjects: 154
Study 2533896 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg t.d.s.
Number of subjects: 154
Study 773484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal noxytiolin (Noxiflex) solution
Number of subjects: 0
Study 773484 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30949182 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) therapy
Number of subjects: 34
Study 27830484 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 120
Study 27830484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 120
Study 27830484 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study 27119829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day co-administered with atorvastatin 20 mg
Number of subjects: 323
Study 27119829 — intervention group
Group type: COMPARATOR
Intervention: Doubling atorvastatin dose
Number of subjects: 323
Study 24508320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus treatment as usual
Number of subjects: 74
Study 24508320 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 74
Study 22395889 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of ocular hypotensive medication
Number of subjects: 432
Study 21299153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10F Double Layer Stent (DLS) (n = 24)
Number of subjects: 49
Study 21299153 — intervention group
Group type: COMPARATOR
Intervention: 10F Tannenbaum Stent (TAN) (n = 25)
Number of subjects: 49
Study 17343552 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at low, medium, and high doses
Number of subjects: 16
Study 16458538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (30 or more drinks per month)
Number of subjects: 0
Study 16458538 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soda consumption (one or more drinks per day)
Number of subjects: 0
Study 16458538 — intervention group
Group type: COMPARATOR
Intervention: Diet soda consumption
Number of subjects: 0
Study 12924682 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-experiential psychotherapy
Number of subjects: 66
Study 12924682 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral psychotherapy
Number of subjects: 66
Study 12924682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 66
Study 10578595 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Indian herbal preparation (CIHP)
Number of subjects: 56
Study 10578595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8694025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose supplementation (0.6 to 1.0 g.kg‐1.d‐1, divided into three doses) for 10 days
Number of subjects: 20
Study 8694025 — intervention group
Group type: COMPARATOR
Intervention: Dextrose supplementation for 10 days (control)
Number of subjects: 20
Study 8694025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose challenge (0.35 g/kg) after overnight fast
Number of subjects: 20
Study 1928975 — intervention group
Group type: EXPERIMENTAL
Intervention: n-of-1 RCT
Number of subjects: 26
Study 6318345 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg per day ketoprofen alone
Number of subjects: 18
Study 6318345 — intervention group
Group type: COMPARATOR
Intervention: 300 mg per day ketoprofen combined with 1,500 mg aspirin
Number of subjects: 18
Study 30387015 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (12 weeks, 3 sessions/week)
Number of subjects: 26
Study 30387015 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 26
Study 27684415 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency ventilation (NIHFV)
Number of subjects: 39
Study 27684415 — intervention group
Group type: COMPARATOR
Intervention: Bi-phasic continuous positive airway pressure (BP-CPAP)
Number of subjects: 39
Study 27684415 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHFV
Number of subjects: 39
Study 27684415 — intervention group
Group type: COMPARATOR
Intervention: BP-CPAP
Number of subjects: 39
Study 26384629 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to a recorded CD of music and songs preferred by the child)
Number of subjects: 50
Study 26384629 — intervention group
Group type: COMPARATOR
Intervention: Control group (listening to a blank CD)
Number of subjects: 50
Study 23790566 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (0, 5, 10, and 20 mg)
Number of subjects: 165
Study 21283923 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fluence (HF) (3.8 J/cm2)
Number of subjects: 46
Study 21283923 — intervention group
Group type: COMPARATOR
Intervention: Lower fluence (LF) (2.5 J/cm2)
Number of subjects: 46
Study 21283923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LF and HF treatments
Number of subjects: 46
Study 19135671 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (4 mg od)
Number of subjects: 28
Study 19135671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg od)
Number of subjects: 28
Study 17357473 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 15380894 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg plain release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Number of subjects: 48
Study 15380894 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg slow release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Number of subjects: 48
Study 15380894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11887109 — intervention group
Group type: COMPARATOR
Intervention: Concentric training (CON, n = 9)
Number of subjects: 23
Study 11887109 — intervention group
Group type: COMPARATOR
Intervention: Concentric-eccentric training (CON-ECC, n = 8)
Number of subjects: 23
Study 11887109 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (NONTX, n = 6)
Number of subjects: 23
Study 9540144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 0
Study 9540144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrophan (metabolite of dextromethorphan)
Number of subjects: 0
Study 9540144 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin-induced hyperalgesia
Number of subjects: 0
Study 8062609 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/day) for 48 months in normotensive patients (NE group)
Number of subjects: 52
Study 8062609 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/day) for 48 months in well-controlled hypertensive patients (HE group)
Number of subjects: 52
Study 8062609 — intervention group
Group type: COMPARATOR
Intervention: No enalapril treatment in normotensive patients (NC group)
Number of subjects: 52
Study 8062609 — intervention group
Group type: COMPARATOR
Intervention: No enalapril treatment in well-controlled hypertensive patients (HC group)
Number of subjects: 52
Study 2643042 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol (nonionic)
Number of subjects: 443
Study 2643042 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate (ionic)
Number of subjects: 443
Study 797515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of nickel (double-blind test)
Number of subjects: 12
Study 797515 — intervention group
Group type: COMPARATOR
Intervention: Intense handling of nickel-contaminated metal objects
Number of subjects: 12
Study 31175814 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Music Therapy (MT)
Number of subjects: 16
Study 31175814 — intervention group
Group type: COMPARATOR
Intervention: Passive Music Therapy (MT)
Number of subjects: 16
Study 28364446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Health Program (SHP) including sleep health education and sleep disorders screening
Number of subjects: 1189
Study 28364446 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at education sessions
Number of subjects: 1189
Study 28364446 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 1189
Study 25387489 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multivariate aerobic training program
Number of subjects: 39
Study 25387489 — intervention group
Group type: COMPARATOR
Intervention: Nontrained group
Number of subjects: 39
Study 23352954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Resistance Circuit (HRC) training
Number of subjects: 37
Study 23352954 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Heavy Strength (TS) training
Number of subjects: 37
Study 23352954 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study 21289017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium infusion (20‐mmol (5 g) magnesium sulfate for 5 consecutive days)
Number of subjects: 46
Study 21289017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19284575 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for cervicitis diagnosis
Number of subjects: 914
Study 19284575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological examination (including friability)
Number of subjects: 914
Study 19284575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of C. trachomatis
Number of subjects: 914
Study 19284575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of N. gonorrhoeae
Number of subjects: 914
Study 17202010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg (n = 25)
Number of subjects: 75
Study 17202010 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg kg(‐1) (n = 25)
Number of subjects: 75
Study 17202010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 75
Study 15130043 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaire facemask and Bionator III appliance
Number of subjects: 30
Study 15130043 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class III malocclusions)
Number of subjects: 30
Study 11524307 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (two 333 mg tablets given three times daily for 180 days)
Number of subjects: 296
Study 11524307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 9773133 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple epidural mixture with adrenaline (bupivacaine 1 mg/ml, fentanyl 2 micrograms/ml, adrenaline 2 micrograms/ml)
Number of subjects: 24
Study 9773133 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion without adrenaline
Number of subjects: 24
Study 9773133 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple epidural mixture with adrenaline
Number of subjects: 24
Study 7824963 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium-labeled DS (dermatan sulfate)
Number of subjects: 0
Study 7824963 — intervention group
Group type: EXPERIMENTAL
Intervention: Native heparin
Number of subjects: 0
Study 7824963 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic degradation
Number of subjects: 0
Study 7824963 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical degradation
Number of subjects: 0
Study 2369494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 73
Study 2369494 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg twice daily
Number of subjects: 73
Study 2369494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 1015603 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear analogue rating (10, 15, and 20 cm lines)
Number of subjects: 0
Study 1015603 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 150 mg intramuscularly
Number of subjects: 0
Study 31686249 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT (67.5 Gy, 2.25 Gy/fraction)
Number of subjects: 69
Study 31686249 — intervention group
Group type: COMPARATOR
Intervention: S-IMRT (70 Gy, 2 Gy/fraction)
Number of subjects: 69
Study 31686249 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Number of subjects: 69
Study 31686249 — intervention group
Group type: COMPARATOR
Intervention: S-IMRT
Number of subjects: 69
Study 31686249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 69
Study 31686249 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 69
Study 31686249 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant metastasis-free survival
Number of subjects: 69
Study 31686249 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional-free survival
Number of subjects: 69
Study 30847839 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 25
Study 30847839 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Program (BHP)
Number of subjects: 25
Study 30847839 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WAIT) control group
Number of subjects: 25
Study 27012822 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (8-week aerobic exercise programme plus usual medical care)
Number of subjects: 50
Study 27012822 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual medical care)
Number of subjects: 50
Study 25956385 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASAD)
Number of subjects: 300
Study 25956385 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring with specialist reassessment (AMSR)
Number of subjects: 300
Study 25956385 — intervention group
Group type: COMPARATOR
Intervention: Investigational shoulder arthroscopy only (AO)
Number of subjects: 300
Study 23379271 — intervention group
Group type: EXPERIMENTAL
Intervention: ToM Intervention (ToMI)
Number of subjects: 30
Study 23379271 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 30
Study 21746944 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 100 mg QD for 24 weeks
Number of subjects: 146